AIHTA - Publications - Search - Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer

Rothschedl, E. and Wolf, S. (2022): Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for the treatment of persistent, recurrent, or metastatic cervical cancer. Oncology Fact Sheet Nr. 91.

[thumbnail of Oncology Fact Sheet Nr.91.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
110kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WP Gynaecology > WP 470-480 Cervix uteri. Cervix diseases
Language:English
Series Name:Oncology Fact Sheet Nr. 91
Deposited on:25 Apr 2022 14:59
Last Modified:16 May 2022 09:31

Repository Staff Only: item control page